其中,一些试验是上市药物为扩大适应证做的“加试题”,少数是未上市新药的探索研究,还有一些是中药的组方。这些临床试验的方案是否合理、伦理是否认真审查、是否对受试者进行保护等,都没有看到权威部门的评审与讨论,试验的安全和有效性令人担忧。
下面,我们就来挨个点评一下,看究竟谁能凭实力“C位出道”,谁是来划水打酱油的。 种子选手 瑞德西韦:体外实验抗病毒活性好,临床有治愈病例 氯喹和羟氯喹:作用原理清晰,体外实验活性好 关于其他在研药物的“比赛评分”,请继续收看腾讯医典“寻找特效药”的(中)篇和(下)篇。 参考文献 [1]. Maria L. Agostini, et al. Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease. mBio, 2018; 9 (2): e00221-18 DOI: 10.1128/mBio.00221-18 [2]. Wang, M., et al., Remdesivir and chloroquine effectively inhibit the recently emergednovel coronavirus (2019-nCoV) in vitro. Cell Research, 2020. [3]. Michelle L. Holshue, et al. First Case of 2019 Novel Coronavirus in the United States. N Engl J Med. https://www./doi/10.1056/NEJMoa2001191 [4]. Martin J Vincent. Chloroquine is a potentinhibitor of SARS coronavirus infection and spread. Virology Journal 2005, 2:69 [5]. Vincent M J , Bergeron E , Benjannet S , et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread[J]. Virology Journal, 2005, 2(1):69. |
|